NCT05514106 - MIBG in Aging and Neurologic Disorders | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Lewy Body DiseaseDementiaParkinsonismMild Cognitive ImpairmentREM Sleep Behavior Disorder

Interventions

DRUG

meta-iodobenzylguanidine (MIBG) (123I)

1 administration of 123I-MIBG for a single SPECT scan

DIAGNOSTIC_TEST

123I-MIBG scintigraphy

SPECT scan involving 123I-MIBG as the ligand

Trial Locations (1)

Mayo Clinic in Rochester, Rochester